#1 Clinical Trials Search in Europe

Pp1815

In the world of medical research, an exciting clinical trial is underway to test the effectiveness of a new treatment for hip and knee joint infections. This study, known as PhagoDAIR I, is investigating the use of bacteriophages, specifically a drug called Pp1815, in combination with traditional antibiotic therapy. The trial aims to help patients with prosthetic joint infections caused by a bacteria called Staphylococcus aureus. This innovative approach could potentially offer new hope for those suffering from these challenging infections.

Table of Contents

What is PP1815?

PP1815 is an innovative medical treatment being studied for its potential to combat certain types of bacterial infections. It belongs to a class of treatments called bacteriophage therapy, which uses viruses (bacteriophages) that specifically target and destroy harmful bacteria[1]. In this case, PP1815 is designed to fight infections caused by a bacterium called Staphylococcus aureus, which is a common cause of serious infections, especially in healthcare settings.

Target Condition: Prosthetic Joint Infections

The main focus of the clinical trial for PP1815 is treating prosthetic joint infections (PJIs) caused by Staphylococcus aureus. These are infections that occur in artificial hip or knee joints, which can be a serious complication after joint replacement surgery[1]. PJIs can cause pain, swelling, and difficulty moving the affected joint, and they can be challenging to treat with conventional antibiotics alone.

How PP1815 Works

PP1815 is a solution for injection that contains bacteriophages specifically targeting Staphylococcus aureus. When injected into the infected area, these bacteriophages seek out and destroy the harmful bacteria without harming human cells. This targeted approach is different from traditional antibiotics, which can affect both harmful and beneficial bacteria in the body[1].

Clinical Trial Details

The clinical trial for PP1815 is called “PhagoDAIR I” and is designed to test the effectiveness and safety of this new treatment. Here are some key points about the trial:

  • It’s a Phase II pilot study, which means it’s an early stage of testing in humans to gather more information about the treatment’s effectiveness and safety[1].
  • The study is randomized and double-blind, meaning participants are randomly assigned to either receive PP1815 or a placebo (salt water solution), and neither the patients nor most of the medical staff know which treatment each participant is receiving[1].
  • The treatment is given alongside a standard procedure called DAIR (Debridement, Antibiotics, and Implant Retention) and antibiotic therapy[1].
  • The main goal is to see how well PP1815 helps control the infection compared to the standard treatment alone[1].

Potential Benefits of PP1815

If successful, PP1815 could offer several benefits for patients with prosthetic joint infections:

  • More effective treatment of infections that are difficult to treat with antibiotics alone[1].
  • Potentially shorter hospital stays and improved quality of life for patients[1].
  • A more targeted approach that may have fewer side effects compared to broad-spectrum antibiotics[1].

Safety Considerations

As with any new medical treatment, safety is a top priority in the PP1815 clinical trial. The researchers will be closely monitoring participants for any side effects or adverse reactions throughout the study. This includes regular physical examinations and blood tests to check for any unexpected effects of the treatment[1].

Eligibility Criteria

The clinical trial has specific criteria for who can participate. Some key points include:

  • Participants must be 18 years or older[1].
  • They must have a confirmed Staphylococcus aureus infection in a hip or knee prosthetic joint[1].
  • The infection must have occurred more than one month after the joint replacement surgery[1].
  • Participants must not have certain medical conditions or be taking medications that could interfere with the study results[1].

It’s important to note that this is a summary of the ongoing research, and PP1815 is not yet approved for general use. If you have a prosthetic joint infection, always consult with your healthcare provider for the most appropriate treatment options available to you.

Aspect Details
Study Name PhagoDAIR I
Study Type Phase II – pilot, randomized, double-blind
Main Objective Estimate infection control rate using DAIR + antibiotics with bacteriophages or placebo
Target Condition Hip or knee prosthetic joint infection due to Staphylococcus aureus
Key Inclusion Criteria Adults ≥18 years, S. aureus infection >1 month post-implantation, susceptible to at least one phage
Treatment Arms 1) DAIR + antibiotics + bacteriophages (Pp1815)
2) DAIR + antibiotics + placebo (NaCl 0.9%)
Primary Endpoint Clinical control of infection (no fever, no worsening pain, no signs of infection)
Secondary Endpoints Safety, phage activity, quality of life, joint function, hospitalization duration
Pp1815 Details Solution for injection, max daily dose 10,000,000,000 PFU/ml, max total dose 40,000,000,000 PFU/ml

FAQ

  • What is Pp1815 and how does it work? Pp1815 is a type of bacteriophage, which is a virus that specifically targets and kills bacteria. In this trial, it's being used to fight Staphylococcus aureus infections in hip and knee joints. It works by attacking the bacteria directly, potentially enhancing the effectiveness of antibiotic treatment.
  • Who is eligible for this clinical trial? The trial is open to adults (18 years and older) with a Staphylococcus aureus infection in their hip or knee prosthetic joint. The infection must have occurred more than one month after the prosthesis was implanted. Participants must meet several other criteria, including having a life expectancy of at least 2 years.
  • What does the treatment involve? The treatment involves a procedure called DAIR (Debridement, Antibiotics, and Implant Retention) combined with antibiotic therapy and either Pp1815 or a placebo (salt water solution). Some patients may receive a single dose, while others might receive multiple doses if the infection returns.
  • What are the potential benefits of this new therapy? The potential benefits include better control of the infection, possibly leading to faster recovery and improved joint function. The study aims to determine if adding Pp1815 to standard treatment can increase the success rate in treating these difficult infections.
  • Are there any risks associated with the trial? As with any clinical trial, there may be risks. The study will closely monitor participants for any adverse effects. Specific risks are not detailed in the provided information, but the trial includes safety assessments throughout the study period. Patients should discuss potential risks with the study doctors before participating.

Ongoing Clinical Trials on Pp1815

  • Study of PP1493 and PP1815 phage therapy for patients with knee or hip joint infections caused by Staphylococcus aureus after prosthetic surgery

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands Spain

  • Study of PP1493 and PP1815 bacteriophages combined with DAIR and antibiotics for treating knee or hip prosthetic joint infections caused by Staphylococcus aureus

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Bacteriophage: A type of virus that specifically infects and destroys bacteria. In this study, bacteriophages are being used as a potential treatment for bacterial infections.
  • Staphylococcus aureus: A type of bacteria that can cause serious infections, particularly in prosthetic joints. It's the specific bacteria targeted in this clinical trial.
  • Prosthetic Joint Infection (PJI): An infection that occurs around an artificial joint, such as a hip or knee replacement. These infections can be difficult to treat and may require special interventions.
  • DAIR: Stands for Debridement, Antibiotics, and Implant Retention. It's a surgical procedure used to treat prosthetic joint infections while keeping the artificial joint in place.
  • Suppressive Antibiotics Therapy (SAT): A long-term antibiotic treatment used to control chronic infections, particularly in cases where the infection can't be completely eliminated.
  • Monomicrobial: An infection caused by a single type of microorganism, in this case, only Staphylococcus aureus.
  • Randomized: A method used in clinical trials where participants are randomly assigned to different treatment groups to reduce bias in the results.
  • Double-Blind: A study design where neither the participants nor the researchers directly involved know who is receiving which treatment, helping to prevent bias.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs. In this study, a salt water solution is used as the placebo.
  • PFU/ml: Stands for Plaque Forming Units per milliliter, a measure used to quantify the amount of active bacteriophages in a solution.

References

  1. http://clinicaltrials.eu/trial/study-on-phage-therapy-with-pp1493-pp1815-and-sodium-chloride-for-patients-with-hip-or-knee-joint-infections-from-staphylococcus-aureus/